Delving into the Latest Updates on UTAA09/17 with Synapse

Overview

Basic Info

Drug Type

γ-δT

Synonyms

CD19-CAR-Vδ1T, UTAA 09, UTAA-09

+ [2]

Target

CD19

Mechanism

CD19 modulators(B-lymphocyte antigen CD19 modulators), Immunologic cytotoxicity, T lymphocyte replacements

Therapeutic Areas

NeoplasmsImmune System DiseasesNervous System Diseases+ [6]

Active Indication

B-Cell LymphomaIdiopathic Inflammatory MyopathiesPBC+ [10]

Inactive Indication-

Originator Organization

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Active Organization

PersonGen BioTherapeutics (Suzhou) Co., Ltd.Third Affiliated Hospital of Nanjing Medical University

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

The main research objective is to evaluate the safety, tolerability, and pharmacokinetic characteristics of UTAA09 cell preparation in the treatment of relapsed/refractory B-cell non Hodgkin's lymphoma patients. The secondary research objective is to explore the clinical efficacy of UTAA09 injection after administration and to explore the content of CD19 positive B cells in peripheral blood after UTAA09 injection administration.

Start Date31 Jul 2024

Sponsor / Collaborator

Third Affiliated Hospital of Nanjing Medical University

NCT06417398 / Not yet recruitingEarly Phase 1

Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases

To evaluate the safety of UTAA09 injection in the treatment of relapsed/refractory (R/R) autoimmune disease (AID).
To evaluate the pharmacokinetic (PK) profile of UTAA09 injection in patients with R/R AID.
To evaluate the pharmacodynamic (PD) characteristics of UTAA09 injection in patients with R/R AID.
To evaluate the initial efficacy of UTAA09 injection in the treatment of R/R AID subjects.
To evaluate the immunogenicity of UTAA09 injection in R/R AID subjects.

Start Date14 May 2024

Sponsor / Collaborator

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

NCT06361745 / RecruitingNot Applicable

Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory

Main purpose:
To evaluate the safety of UTAA09 injection in the treatment of relapsed/refractory (R/R) autoimmune disease (AID).
Secondary purpose:
To evaluate the pharmacokinetic (PK) profile of UTAA09 injection in patients with R/R AID.
To evaluate the pharmacodynamic (PD) characteristics of UTAA09 injection in patients with R/R AID.
To evaluate the initial efficacy of UTAA09 injection in the treatment of R/R AID subjects.
To evaluate the immunogenicity of UTAA09 injection in R/R AID subjects.

Start Date02 Apr 2024

Sponsor / Collaborator

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

100 Clinical Results associated with UTAA09/17

Login to view more data

100 Translational Medicine associated with UTAA09/17

Login to view more data

100 Patents (Medical) associated with UTAA09/17

Login to view more data

100 Deals associated with UTAA09/17

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
B-Cell Lymphoma	Phase 1	CN	Third Affiliated Hospital of Nanjing Medical University	31 Jul 2024
Idiopathic Inflammatory Myopathies	Phase 1	-	PersonGen BioTherapeutics (Suzhou) Co., Ltd.	14 May 2024
PBC	Phase 1	-	PersonGen BioTherapeutics (Suzhou) Co., Ltd.	14 May 2024
Purpura, Thrombocytopenic, Idiopathic	Phase 1	-	PersonGen BioTherapeutics (Suzhou) Co., Ltd.	14 May 2024
Scleroderma, Systemic	Phase 1	-	PersonGen BioTherapeutics (Suzhou) Co., Ltd.	14 May 2024
Sjogren's Syndrome	Phase 1	-	PersonGen BioTherapeutics (Suzhou) Co., Ltd.	14 May 2024
Systemic Lupus Erythematosus	Phase 1	-	PersonGen BioTherapeutics (Suzhou) Co., Ltd.	14 May 2024
CD19 positive B-Cell Lymphoma	Phase 1	CN	PersonGen BioTherapeutics (Suzhou) Co., Ltd.	01 Oct 2023
Hematologic Neoplasms	Phase 1	CN	PersonGen BioTherapeutics (Suzhou) Co., Ltd.	01 Oct 2023
B-Cell Malignant Neoplasm	Preclinical	CN	PersonGen BioTherapeutics (Suzhou) Co., Ltd.	22 Mar 2024